Ocular surface immunity: Homeostatic mechanisms and their disruption in dry eye disease

DSpace/Manakin Repository

Ocular surface immunity: Homeostatic mechanisms and their disruption in dry eye disease

Citable link to this page


Title: Ocular surface immunity: Homeostatic mechanisms and their disruption in dry eye disease
Author: Barabino, Stefano; Chen, Yihe; Chauhan, Sunil Kumar; Dana, Reza

Note: Order does not necessarily reflect citation order of authors.

Citation: Barabino, Stefano, Yihe Chen, Sunil Chauhan, and Reza Dana. 2012. “Ocular Surface Immunity: Homeostatic Mechanisms and Their Disruption in Dry Eye Disease.” Progress in Retinal and Eye Research 31 (3) (May): 271–285. doi:10.1016/j.preteyeres.2012.02.003.
Full Text & Related Files:
Abstract: The tear film, lacrimal glands, corneal and conjunctival epithelia and Meibomian glands work together as a lacrimal functional unit (LFU) to preserve the integrity and function of the ocular surface. The integrity of this unit is necessary for the health and normal function of the eye and visual system. Nervous connections and systemic hormones are well known factors that maintain the homeostasis of the ocular surface. They control the response to internal and external stimuli. Our and others’ studies show that immunological mechanisms also play a pivotal role in regulating the ocular surface environment. Our studies demonstrate how anti-inflammatory factors such as the expression of vascular endothelial growth factor receptor-3 (VEGFR-3) in corneal cells, immature corneal resident antigen-presenting cells, and regulatory T cells play an active role in protecting the ocular surface.

Dry eye disease (DED) affects millions of people worldwide and negatively influences the quality of life for patients. In its most severe forms, DED may lead to blindness. The etiology and pathogenesis of DED remain largely unclear. Nonetheless, in this review we summarize the role of the disruption of afferent and efferent immunoregulatory mechanisms that are responsible for the chronicity of the disease, its symptoms, and its clinical signs. We illustrate current anti-inflammatory treatments for DED and propose that prevention of the disruption of immunoregulatory mechanisms may represent a promising therapeutic strategy towards controlling ocular surface inflammation.
Published Version: 10.1016/j.preteyeres.2012.02.003
Other Sources: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3334398/
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:34854260
Downloads of this work:

Show full Dublin Core record

This item appears in the following Collection(s)


Search DASH

Advanced Search